By Matt Jones

NEW YORK (GenomeWeb News) – If the new technologies of the genomics era are going to be useful in addressing public health outcomes, steps should be taken to improve the evidence supporting their value, to educate the healthcare workforce and the public about their use, and to ensure their safety and effectiveness and applicability to chronic diseases, according to a report about the state of public health genomics.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.